OXFORD IMMUNOTEC LIMITED NONSTATUTORY STOCK OPTION AGREEMENT GRANTED UNDER AMENDED AND RESTATED 2008 STOCK INCENTIVE PLAN FOR NON-CALIFORNIA OPTION HOLDERS

Exhibit 10.37

OXFORD IMMUNOTEC LIMITED

NONSTATUTORY STOCK OPTION AGREEMENT GRANTED UNDER

AMENDED AND RESTATED 2008 STOCK INCENTIVE PLAN

FOR NON-CALIFORNIA OPTION HOLDERS

THIS AGREEMENT is made      day              20[    ]

BETWEEN:-

OXFORD IMMUNOTEC LIMITED (reg. no. 4516079) whose registered office is at 115D Innovation Drive, Milton Park, Abingdon, Oxfordshire, OX14 4RZ (the “Company”); and

                    , a non-executive director of the Company (the “Option Holder”) on                     , (the “Date of Grant”)

1) Option Grant. The Company hereby grants to the Option Holder with effect from the above date an Option to subscribe for up to              Ordinary Shares of 0.1p each in the capital of the Company (the “Shares”) at a price of $         per Ordinary Share (the “Per Share Exercise Price”) (together, the “Option”).

For purposes of determining the Vesting Percentage in section 3 and the Final Expiration Date below, the “Start Date” for this Option is                     .

The Final Expiration Date of this Option is nine years three hundred sixty-four (364) days after the earlier of (i) the Start Date or (ii) the Date of Grant.

2) Governing Plan. It is intended that the Option evidenced by this agreement shall not be an incentive stock Option as defined in Section 422 of the United States’ Internal Revenue Code of 1986, as amended, and any regulations promulgated thereunder (the “Code”). The Option is subject to the rules of the Oxford Immunotec Limited Amended and Restated 2008 Stock Incentive Plan (a copy of which is set out in Schedule 1 of this Agreement) (the “Plan”). If a matter is explicitly addressed in this Option, the language of this Option shall prevail. If a matter is omitted in this Option, the language of the Plan shall prevail. If there is a conflict between this Option and the Plan, the language of the Plan shall prevail. The Option Holder may also be referred to as a “Participant” in the Plan.

Except as otherwise indicated by the context, the term “Option Holder”, as used in this Option, shall be deemed to include any person who acquires the right to exercise this Option validly under its terms.

3) Definition of Vested Shares. The number of Ordinary Shares which may be acquired at any time (“Vested Shares”) can be determined by (x) multiplying the number of Shares set forth in Section 1 by (y) the Vesting Percentage set forth in this Section 3 and (z) subtracting the number of Shares previously acquired by exercising this Option. Unless otherwise determined by the Board of Directors of the Company, this Option shall never be exercisable for more than the Vested Shares.

a) The Vesting Percentage cannot exceed 100%. On or prior to the Final Expiration Date (as defined in Section 1) the Vesting Percentage will be determined by multiplying the number of completed months of service since the Start Date (“Completed Service”) set forth in Section 1 by 2.083%. For example, after 26 months of Completed Service, the Vesting Percentage for this Option will be 54.16%; after 36 months of Completed Service, it will be 75%; and after 48 months of Completed Service it will be 100%. After the Final Expiration Date, the Vesting Percentage will be zero.

b) Notwithstanding Section 3(a), the Vesting Percentage for this Option will be 0% until 12 months have elapsed since the Start Date of the first option granted to the Option Holder by the Company.

1

4) Transferability. This Option may not be sold, assigned, transferred, pledged or otherwise encumbered by the Option Holder, either voluntarily or by operation of law, except by will or the laws of descent and distribution (or the local equivalent) and, during the lifetime of the Option Holder, this Option shall be exercisable only by the Option Holder. This Option shall immediately cease to be exercisable and shall lapse if:

a) it is transferred or assigned (other than in the event of death to the Option Holder’s duly designated heirs or executors (or the local equivalent)), mortgaged, charged or otherwise disposed of by the Option Holder; or

b) the Option Holder is adjudged bankrupt or an interim order is made because he intends to propose a voluntary arrangement to his creditors; or

c) the Option Holder makes or proposes a voluntary arrangement, or any other scheme or arrangement in relation to his debts, with his creditors or any section of them; or

d) the Option Holder is otherwise deprived (except on death) of the legal or beneficial ownership of the Option by operation of law or by doing or omitting to do anything which causes him to be so deprived.

The date of any of the events set forth above shall be deemed to be the “Unauthorized Transfer Date”.

5) Exercise of the Option

a) Option Expiration Date. This Option shall expire and no longer be exercisable for any Vested Shares on the earlier of (a) the Unauthorized Transfer Date (defined in Section 4), (b) the Final Expiration Date (defined in Section 1) or the Early Termination Date (defined in Section 5(d)).

b) Form of Exercise. The exercise of this Option shall be effective on the date (the “Exercise Date”) the Company receives at its principal office the Notice of Exercise attached hereto, duly signed by the Option Holder, and accompanied by this agreement, and payment in full in the manner as provided below. The Option Holder may purchase less than the number of shares covered hereby, provided that any partial exercise of this Option must be for whole integer numbers of Shares.

c) Deed of Adherence. Exercise of the Option is conditional upon the Option Holder executing, if so required by the Company, a deed of adherence (in such form as may be required by the Company) with the Company and all persons who are holders of shares in the capital of the Company at the date of exercise of the Option whereby the Option Holder becomes a party to any Shareholders’ Agreement or other document having a similar effect which is in force between the Company and all persons who, at the date of exercise of the Option, are holders of shares in the capital of the Company. A copy of the current deed of adherence which is in force as of the date of this Option is available from the Company upon request.

d) Early Termination of the Option: In the circumstances set forth below, this Option may terminate prior to the Final Expiration Date. In each instance below, the conditions for the termination, the method for calculating the Vesting Percentage and the determination of the Early Termination Date are set forth.

i) Regular Termination: If the Option Holder ceases to be a non-executive director of the Company for any reason except as provided in paragraphs (ii) and (iii) below, the date of such event shall be deemed to be the “Service Termination Date” and shall be used to determine the Vesting Percentage in Section 3 and there shall be no Early Termination Date.

ii) Death or Disability. If the Option Holder dies, then the date of death shall be deemed to be the “Service Termination Date” and shall be used to determine the Vesting Percentage in Section 3 and and there shall be no Early Termination Date. If the Option Holder ceases employment by reason of disability (as determined by the Board of Directors), then the date of cessation of service shall be deemed to be the “Service Termination Date” and shall be used to determine the Vesting Percentage in Section 3 and and there shall be no Early Termination Date.

2

iii) For Cause. If, prior to the Final Expiration Date, the Option Holder’s service is terminated by the Company for Cause (as defined below), the Vesting Percentage and the number of Vested Shares will become Zero upon termination and the effective date of such termination shall be deemed to be the “Service Termination Date” and shall also be the Early Termination Date. If the Option Holder is party to a service or severance agreement with the Company that contains a definition of “cause” for termination of service, “Cause” shall have the meaning ascribed to such term in such agreement. Otherwise, “Cause” shall mean willful misconduct by the Option Holder or willful failure by the Option Holder to perform his or her responsibilities to the Company (including, without limitation, breach by the Option Holder of any provision of any employment, consulting, advisory, nondisclosure, non-competition or other similar agreement between the Option Holder and the Company), as determined by the Company, which determination shall be conclusive. The Option Holder shall be considered to have been discharged for Cause if the Company determines, within one month after the Option Holder’s resignation, that discharge for Cause was warranted.

iv) Change of Control. Section 9 also provides another instance when the Vesting Percentage may be calculated and the Early Termination Date may be determined.

v) Notwithstanding the foregoing paragraphs (i) through (iv), the Option may only be exercised where the Option Holder, prior to the Option Expiration Date, has not been notified by the Company in writing that he/she has violated the non-competition or confidentiality provisions of any employment or service contract, confidentiality and nondisclosure agreement or other agreement between the Option Holder and the Company.

6) Payment upon Exercise. Shares in the capital of the Company purchased upon the exercise of an Option granted under the Plan shall be paid for as follows:

a) in cash or by cheque, payable to the order of the Company;

b) when shares in the capital of the Company are registered under the Securities Exchange Act of 1934, as amended or UK equivalent (the “Exchange Act”), by (i) delivery of an irrevocable and unconditional undertaking by a creditworthy broker to deliver promptly to the Company sufficient funds to pay the exercise price and any required tax withholding or (ii) delivery by the Option Holder to the Company of a copy of irrevocable and unconditional instructions to a creditworthy broker to deliver promptly to the Company cash or a check sufficient to pay the exercise price and any required tax withholding;

c) when shares in the capital of the Company are registered under the Exchange Act, by delivery (either by actual delivery or attestation) of shares in the capital of the Company owned by the Option Holder valued at their fair market value as determined by (or in a manner approved by) the Board (“Fair Market Value”), provided (i) such method of payment is then permitted under applicable law and has no adverse tax or accounting consequences for the Company, (ii) such shares, if acquired directly from the Company, were owned by the Option Holder for such minimum period of time, if any, as may be established by the Board in its discretion and (iii) such shares are not subject to any repurchase, forfeiture, unfulfilled vesting or other similar requirements;

d) by any combination of the above permitted forms of payment.

7) Additional Provisions Regarding Exercise. Further provisions governing the manner in which and the time at which the Option may be exercised are set out in the Plan.

3

8) Changes in Capitalization. In the event of change in the capitalization of the Company (including but not limited to, stock splits or stock consolidations) the number of Shares covered by this Option and the Exercise Price of the Shares may be adjusted in such manner as the Board shall determine as set forth in the Plan.

9) Change of Control. Upon a Change in Control Event, as defined below, prior to the expiration of the 12 month cliff vesting period described in Section 3(b) hereof, the provisions of Section 3(b) shall be disapplied and the vesting of this option shall follow the terms set out in Section 3(a) hereof. In addition, upon a Change in Control Event, the Vesting Percentage of this Option will become 100%. Unless otherwise provided by the Board at the time of or prior to the consummation of such Change in Control Event, (i) the Option Holder may exercise all or any part of the Option up until the time immediately prior to the consummation of the Change in Control Event and (ii) any unexercised portion of the Option will terminate on such Change in Control Event. A “Change in Control Event” shall occur if the Company (A) shall come under the control of another person or persons as defined in the Plan or (B) sells substantially all of its assets to a third party.

10) Tax Indemnification: The Option Holder agrees and undertakes with the Company that no Shares will be issued pursuant to the exercise of this Option unless and until the Option Holder pays to the Company, or makes provision satisfactory to the Company for payment of, any federal, state or local withholding taxes required by law to be withheld in respect of this Option.

11) Nothing in this Agreement shall be taken to impose any restriction or limitation upon the exercise by the members of the Company of their rights to make any alteration to the Articles of Association or the share capital of the Company.

12) Nothing in this Agreement shall be construed to grant the Option Holder the right to continued employment, service or any other relationship with the Company. The Company expressly reserves the right at any time to dismiss or otherwise terminate its relationship with the Option Holder free from any liability or claim under the Plan, except as expressly provided herein.

13) Details of all restrictions attaching to the Ordinary Shares which may be acquired upon the exercise of the Option are contained in the Articles of Association of the Company (a copy of which can be obtained from the Company Secretary).

EXECUTED as a Deed by the parties the day and year first before written.

EXECUTED as a DEED

by OXFORD IMMUNOTEC LIMITED

acting by two duly authorized officers

in the presence of:

4

OXFORD IMMUNOTEC LIMITED

NOTICE OF STOCK OPTION EXERCISE

Date:                    

Oxford Immunotec Limited

115D Innovation Drive

Milton Park

Abingdon

Oxfordshire

OX14 4RZ

Attention: Company Secretary

Dear Sir or Madam:

I am the holder of a Non-Statutory Stock Option granted to me under the Oxford Immunotec Limited (the “Company”) Amended and Restated 2008 Stock Incentive Plan on                      for the purchase of              ordinary shares in the capital of the Company at a purchase price of £         per share.

I hereby exercise my option to purchase             ¹ ordinary shares in the capital of the Company (the “Shares”), for which I have enclosed a check for $         in favour of “Oxford Immunotec Limited” as payment in full of the option price and return the original Option Agreement and all copies to the Company.

I request that I be registered as the holder of such ordinary shares and a definitive certificate for such shares be prepared in my name.

I understand that I have the right, subject to the restrictions noted below and any other applicable restrictions, including without limitation any insider trading policies and lock-up agreements, to sell the shares, and the Company agrees to make the certificate available to me or my broker to enable me to effect such sales.

I represent, warrant and covenant as follows:

1. I am purchasing the Shares for my own account for investment only, and not with a view to, or for sale in connection with, any distribution of the Shares in violation of the Securities Act of 1933 (the “Securities Act”), or any rule or regulation under the Securities Act.

2. I have had such opportunity as I have deemed adequate to obtain from representatives of the Company such information as is necessary to permit me to evaluate the merits and risks of my investment in the Company.

- 1 -

3. I have sufficient experience in business, financial and investment matters to be able to evaluate the risks involved in the purchase of the Shares and to make an informed investment decision with respect to such purchase.

4. I can afford a complete loss of the value of the Shares and am able to bear the economic risk of holding such Shares for an indefinite period.

5. I understand that (i) the Shares have not been registered under the Securities Act and are “restricted securities” within the meaning of Rule 144 under the Securities Act, (ii) the Shares cannot be sold, transferred or otherwise disposed of unless they are subsequently registered under the Securities Act or an exemption from registration is then available; (iii) in any event, the exemption from registration under Rule 144 will not be available for at least one year and even then will not be available unless a public market then exists for the shares, adequate information concerning the Company is then available to the public, and other terms and conditions of Rule 144 are complied with; and (iv) there is now no registration statement on file with the Securities and Exchange Commission with respect to any stock of the Company and the Company has no obligation or current intention to register the Shares under the Securities Act.

6. I agree that, if requested by the Company or any representative of the underwriters (the “Managing Underwriter”) in connection with any registration of the offering of any securities of the Company under the Securities Act, I shall not sell or otherwise transfer any Shares or other securities of the Company during the 180 day period (or such other period as may be requested in writing by the Managing Underwriter and agreed to in writing by the Company not to exceed 180 days)(the “Market Standoff Period”) following the effective date of a registration statement of the Company filed under the Securities Act. Such restriction shall apply only to the first registration statement of the Company to become effective under the Securities Act that includes securities to be sold on behalf of the Company to the public in an underwritten public offering under the Securities Act. The Company may impose stop-transfer instructions with respect to securities subject to the foregoing restrictions until the end of such Market Standoff Period.

- 2 -

SCHEDULE 1

Oxford Immunotec Limited

AMENDED AND RESTATED 2008 STOCK INCENTIVE PLAN

The purpose of this Amended and Restated 2008 Stock Incentive Plan (the “Plan”) of Oxford Immunotec Limited, a company registered in England and Wales under No. 4516079 (the “Company”), is to advance the interests of the Company’s stockholders by enhancing the Company’s ability to attract, retain and motivate persons who are expected to make important contributions to the Company and by providing such persons with equity ownership opportunities and performance-based incentives that are intended to better align the interests of such persons with those of the Company’s stockholders. Except where the context otherwise requires, the term “Company” shall include any of the Company’s present or future parent or subsidiary corporations as defined in Sections 424(e) or (f) of the Internal Revenue Code of 1986, as amended, and any regulations promulgated thereunder (the “Code”) and any other business venture (including, without limitation, joint venture or limited liability company) in which the Company has a controlling interest, as determined by the Board of Directors of the Company (the “Board”).

All of the Company’s employees, officers, directors, consultants and advisors are eligible to be granted options, restricted stock, restricted stock units (“RSUs”) and other stock-based awards (each, an “Award”) under the Plan. Each person who receives an Award under the Plan is deemed a “Participant”.

- 3 -

If any Award expires or is terminated, surrendered or cancelled without having been fully exercised or is forfeited in whole or in part (including as the result of shares in the capital of the Company being repurchased by the Company at the original issuance price pursuant to a contractual repurchase right) or results in any such shares not being issued, the unused shares covered by such an Award shall again be available for the grant of Awards under the Plan. Further, shares in the capital of the Company tendered to the Company by a Participant to exercise an Award shall be added to the number of shares available for the grant of Awards under the Plan. However, in the case of Incentive Stock Options (as hereinafter defined), the foregoing provisions shall be subject to any limitations under the Code. Shares issued under the Plan may consist in whole or in part of authorized but unissued shares or treasury shares.

- 4 -

- 5 -

- 6 -

Other Awards of shares in the capital of the Company, and other Awards that are valued in whole or in part by reference to, or are otherwise based on, shares in the capital of the Company or other property, may be granted hereunder to Participants (“Other Stock-Based Awards”), including without limitation stock appreciation rights (“SARs”) and Awards entitling recipients to receive shares in the capital of the Company to be delivered in the future. Such Other Stock-Based Awards shall also be available as a form of payment in the settlement of other Awards granted under the Plan or as payment in lieu of compensation to which a Participant is otherwise entitled. Other Stock-Based Awards may be paid in shares in the capital of the Company or cash, as the Board shall determine. Subject to the provisions of the Plan, the Board shall determine the terms and conditions of each Other Stock-Based Award, including any purchase price applicable thereto.

- 7 -

the Board may take any one or more of the following actions as to all or any (or any portion of) outstanding Awards other than Restricted Stock Awards on such terms as the Board determines: (A) upon written notice to a Participant, provide that the Participant’s unexercised Awards will terminate immediately prior to the consummation of such change in Control event unless exercised by the Participant within a specified period following the date of such notice, (B) provide that

- 8 -

Awards shall be assumed, or substantially equivalent Awards shall be substituted, by the acquiring or succeeding corporation (or an affiliate thereof), (C) provide that outstanding Awards shall become exercisable in whole or in part prior to or upon such change in Control event, (D) in the event of a change in Control event under the terms of which holders of shares in the capital of the Company will receive upon consummation thereof a cash payment for each share surrendered in the change in Control event (the “Acquisition Price”), make or provide for a cash payment to a Participant equal to the excess, if any, of (y) the Acquisition Price times the number of shares subject to the Participant’s Awards (to the extent the exercise price does not exceed the Acquisition Price) over (z) the aggregate exercise price of all such outstanding Awards and any applicable tax withholdings, in exchange for the termination of such Awards, (E) provide that, in connection with a liquidation or dissolution of the Company, Awards shall convert into the right to receive liquidation proceeds (if applicable, net of the exercise price thereof and any applicable tax withholdings) and (F) any combination of the foregoing. In taking any of the actions permitted under this Section 8.2, the Board shall not be obligated by the Plan to treat all Awards, all Awards held by a Participant, or all Awards of the same type, identically.

- 9 -

On a sale of substantially all of the assets of the Company, the provisions of Section 8.2 (Change of Control) shall apply to the extent that the Board may take any of the actions described at (A), (B), (C), (D), (E) or (F) therein in relation to outstanding Awards.

- 10 -

- 11 -

- 12 -

Oxford Immunotec Limited

AMENDED AND RESTATED 2008 STOCK INCENTIVE PLAN

CALIFORNIA SUPPLEMENT

Pursuant to Section 10.5 of the Plan, the Board has adopted this supplement for purposes of satisfying the requirements of Section 25102(o) of the California Law:

Any Awards granted under the Plan to a Participant who is a resident of the State of California on the date of grant (a “California Participant”) shall be subject to the following additional limitations, terms and conditions:

The terms of all Awards granted to a California Participant under Section 7 of the Plan shall comply, to the extent applicable, with Section 260.140.41, Section 260.140.42, Section 260.140.45 and Section 260.140.46 of the California Code of Regulations.

No Award granted to a California Participant shall become exercisable, vested or realizable, as applicable to such Award, unless the Plan has been approved by the holders of a majority of the Company’s outstanding voting securities by the later of (i) within 12 months before or after the date the Plan was adopted by the Board or (ii) prior to or within 12 months of the granting of any Award to a California Participant.